(Reuters) – GSK said on Monday its cancer drug Jemperli along with chemotherapy and followed by maintenance therapy Zejula met the primary goal of progression-free survival in patients with advanced or recurrent endometrial cancer in a late-stage trial.
The British company said the trial met the primary goal with a “statistically significant and clinically meaningful” benefit observed in both the overall patient population and in a subpopulation of patients with certain types of tumours.
(Reporting by Aby Jose Koilparambil in Bengaluru; Editing by Sonia Cheema)
